We found that human melanoma SEKI and neuroepithelioma NAGAI cells, which are known to secrete high concentrations of leukemia inhibitory factor (LIF), also secrete high levels of hepatocyte growth factor (HGF). We therefore examined the role of LIF in HGF expression and examined the human HGF promoter. The expression of both LIF and HGF mRNA is very low in HEK293 cells. Treatment of these cells with LIF stimulated the expression of HGF mRNA. The cis-acting regulatory element of the HGF promoter in SEKI and 293 cells was analysed by means of a transient expression assay. By deletion analysis, we showed that the region comprising the À181 to À73 bp was required for full activity of the HGF promoter in SEKI cells and for LIF responsiveness of 293 cells. This region contains putative consensus sequences for the Stat and NF-IL6 (C/EBP b) transcription factors. The activity of the HGF promoter was abolished by mutation of the Stat site at À99/À91, while the activity only slightly decreased on mutation of the NF-IL6 site. Treatment with anti-LIF antibodies or interruption of Stat3 signaling by dominant-negative Stat3 also reduced the HGF promoter activity. Stat3 activation was constitutive in SEKI cells and induced on treatment of 293 cells with LIF. These results suggest that cytokines, growth factors and oncogenes (v-Src, etc.) that activate Stat3 are important regulators of HGF expression.
Introduction
HGF is an inducible cytokine involved in organ development during embryogenesis and tissue regeneration (Nakamura et al., 1984; Matsumoto and Nakamura, 1996) . It exhibits potent motogenic activity toward various carcinoma cells, leading to dissociation, scattering and migration of the cells (Weidner et al., 1991) . During the analysis of paracrine motility factors as to pancreatic carcinoma KP-3 cells, we found that two human cell lines, SEKI melanoma and NAGAI neuroepithelioma ones, secrete high concentrations of hepatocyte growth factor (HGF). In the conditioned media of confluent SEKI and NAGAI cells, 5-28 and 16-17 ng/ml of HGF, respectively, were detected with a human HGF immunoassay system (unpublished results). Although it is known that some cancer cells secrete HGF, we could not detect HGF (o4 pg/ml) in the conditioned media of 16 other kinds of tumor and normal cells, including medulloblastoma (MED-3 and ONS-76), gastric carcinoma (KATO III and MKN-1), monocytic leukemia (THP-1), pancreatic carcinoma (KP-3), choriocarcinoma (BeWo, JAR and NJG), hepatocarcinoma (Hep G2), pituitary tumor (MtT/E and MtT/S) and human embryonic kidney 293 ones. SEKI and NAGAI are thus unique cell lines that secrete high concentrations of leukemia inhibitory factor (LIF) (Kamohara et al., 1994; Iseki et al., 1995) . LIF is a member of the interleukin (IL)-6-type cytokine family that was initially identified as a factor that inhibits the proliferation and induces macrophage differentiation of the mouse myeloid leukemia cells (Tomida et al., 1984; Lowe et al., 1989) . The IL-6-type cytokines mainly activate Stat3 (signal transducers and activators of transcription 3) and NF-IL6 (C/EBP b) by activating a common receptor subunit, gp130 (Akira et al., 1994; Tomida et al., 1999) . We were interested in the apparent correlation between HGF and LIF production. HGF is mainly produced by mesenchymal cells and its production is stimulated in the presence of various cytokines, such as IL-1 and fibroblast growth factors (Tamura et al., 1993; Nakamura et al., 1997) . The nucleotide sequences of the promoter regions of the human, mouse and rat HGF genes have been reported (Miyazawa et al., 1991; Liu et al., 1994) . The cis-acting regulatory elements of the mouse HGF promoter have also been reported (Jiang and Zarnegar, 1997; Hung and Elliott, 2001 ), but they are not conserved in the human gene. Structural and functional characterization of the human HGF gene promoter has not been performed yet. In the present study, we examined the roles of LIF and transcription factors, such as Stat3, in expression of the human HGF gene.
Results

Induction by LIF of HGF mRNA in 293 cells
We first examined the effect of LIF on expression of the HGF gene in 293 cells. We chose these cells because they do not secrete either HGF or LIF, but express LIF receptors (Tomida et al., 1990) . The mRNA level was determined by real-time quantitative RT-PCR using a LightCycler. Treatment of 293 cells with LIF caused induction of HGF mRNA within 3 h and a threefold increase in transcription of the gene after 10 h (Figure 1 ). On the other hand, treatment of the cells with HGF (50 ng/ml) did not induce LIF mRNA. In SEKI and NAGAI cells, high levels of LIF and HGF mRNA were constitutively expressed (data not shown).
Identification of a cis-acting element within the HGF promoter
Next, to identify regulatory sequences that mediate expression of the human HGF gene, sequences 5 0 to the HGF coding region were cloned using a PCR method and placental DNA. A set of 5 0 deletion mutants with endpoints at À1029, À293, À181 and À73 bp relative to the transcription start site (Miyazawa et al., 1991) was generated and fused to a luciferase reporter vector, pGL2-basic (Figure 2 ). These constructs and the pGL2-basic vector were transfected transiently into SEKI and 293 cells. LIF was subsequently added to the 293 culture. Neuroepithelioma NAGAI cells were not transfected in the presence of various kinds of transfection reagents. The transfection of the HGF-1029 and HGF-293 constructs into SEKI cells yielded levels of luciferase activity of about 145-fold the pGL2-basic control one (Figure 3 ), indicating that these segments exhibit promoter activity and that the transcription factors responsible for HGF expression are activated in SEKI cells. In 293 cells, the basal expression of these The nucleotide sequence of the proximal region up to À293 bp was determined and found to be identical to that previously reported (Miyazawa et al., 1991) . The consensus sequences for the NF-IL6 binding element (Akira et al., 1990) and STATx binding element (Horvath et al., 1995; Ehret et al., 2001) are present between positions À151 and À91 (Figure 2 ). The Stat consensus sequence (TTACCGTAA) is a palindrome and closely resembles a high-affinity mutant (TTCCCGTAA) of the Stat3-binding site, the sisinducible element (SIE) in the c-fos promoter (Wagner et al., 1990 ). To determine whether or not the NF-IL6 and Stat sites regulate HGF transcription, we introduced mutations into these sequences within the HGF-293 construct. The mutant and wild-type (HGF-293) plasmids were transfected into SEKI and 293 cells. A dominant-negative Stat3 expression vector (O'Farrell et al., 1998; Tomida et al., 1999) was also cotransfected with the HGF-293 construct to determine whether or not Stat3 is involved in the activation of the HGF gene promoter. As shown in Figure 4 , a mutation in the Stat element reduced the promoter activity by >80% in SEKI cells and the LIF responsiveness by 85% in 293 cells. The mutation in the NF-IL6 motif also reduced the promoter activity, although to a lesser degree than the Stat mutation. Furthermore, expression of dominant-negative Stat3 inhibited the HGF promoter activity in SEKI cells and the LIF responsiveness of 293 cells. This effect was comparable to that of the introduction of a mutation into the Stat element. The empty vector, pRc/CMV, did not affect the promoter activity (data not shown). Next, we examined the binding of activated Stat3 to the HGF promoter. An oligonucleotide, HGF (À105BÀ86), containing the putative HGF Stat-binding site at À99/À91 was used as a probe for electrophoretic mobility shift assay (EMSA). The 293 cells that overexpress Stat3 were used for the experiment, because it seems that an individual natural Stat3-binding site exhibits weak binding affinity and a background binding activity (Wagner et al., 1990; Zhong et al., 1994; Horvath et al., 1995; Yu et al., 1995; Niu et al., 2002) . (Seidel et al., 1995) at À114/À107 could not compete with HGF (À105BÀ86). These results indicate that Stat3 binds to the HGF promoter at À99/À91.
Effect of LIF secreted from SEKI cells
In the conditioned medium of SEKI cells, about 2 ng/ml of LIF was detected with an immunoassay system (Kamohara et al., 1994; Iseki et al., 1995) . The expression level of LIF mRNA in SEKI cells was 360-fold higher than that in 293 cells (data not shown). We next examined the biological activity of the conditioned medium of SEKI cells. Varying concentrations of the conditioned medium and of recombinant LIF were added to 293 cells, and then the effect on the HGF promoter activity was determined. LIF at a concentration of 1 ng/ml or 1% conditioned medium was sufficient for stimulation of the HGF promoter activity (Figure 7a ) and phosphorylation of Stat3 (Figure 5b ). These results suggest that the expression of HGF gene in SEKI cells is stimulated by LIF produced endogenously.
Discussion
In the present study, we showed that HGF expression in SEKI cells and its induction in 293 cells by LIF are mainly dependent on Stat3, and revealed a novel cisacting Stat element comprising À99 to À91 bp in the 5 0 -flanking region of the HGF gene. The nucleotide sequence of this site is completely conserved in the human, mouse and rat genes. Hung and Elliott (2001) reported the cooperative effect of c-Src tyrosine kinase and Stat3 on the activation of HGF expression in mouse mammary carcinoma cells. The region comprising À254 to À70 bp is required for the c-Src and Stat3 responsiveness of the mouse HGF promoter. This is in accord with the present results. However, they proposed two Stat3 binding sites (À149 and À110), which are different from the present Stat site (À99 to À91), judging from the results of EMSA involving probes corresponding to the individual Stat3 consensus sites (À149 and À110), but they did not examine the present Stat site (À99) and Figure 7 Anti-LIF antibodies reduce the HGF promoter activity in SEKI cells (a) and neutralize the activity secreted by SEKI cells, which stimulates the promoter activity in 293 cells (b). SEKI and 293 cells were transfected with the HGF-1029 construct and pRL-TK plasmid. After 24 h, anti-LIF antibodies (80 mg/80 ml), LIF (10 ng), or an equal volume of PBS (control) was added to the culture of SEKI cells. Varying concentrations of LIF and of conditioned medium of SEKI cells treated with or without anti-LIF antibodies (50 ml) were added into the culture (1 ml) of 293 cells. The treatment of LIF and the conditioned medium with the antibodies was performed at room temperature for 60 min. Luciferase activity was determined at 38 h post-transfection, and is expressed as % of the control value. The values are means þ s.e. for duplicate transfections. Two additional experiments were performed with similar results Another study (Jiang and Zarnegar, 1997) involving NIH3T3 fibroblasts revealed that a regulatory element is located between À6 and þ 7 bp in the mouse HGF promoter region, and that NF-IL6 (C/EBP b) binds to this region. However, the nucleotide sequence of this region is not conserved in the human gene. NF-IL6 binding element is located between À151 and À143 bp in the human HGF promoter region. The mutation in the binding element decreased the promoter activity, although to a lesser degree than the Stat mutation (Figure 4) . The result suggests that NF-IL6 participates at least partly in the HGF gene expression. In human fibroblasts, HGF mRNA is induced by IL-1 and tumor necrosis factor-a (Tamura et al., 1993; Nakamura et al., 1997) . NF-IL6, but not Stat3, is activated by these cytokines (Akira et al., 1990) . Therefore, it is likely that NF-IL6 plays an important role in such a case. Further studies will be necessary to elucidate a role of the NF-IL6 binding element in the HGF gene expression.
SEKI cells secreted a high concentration of a factor(s) that stimulated the HGF promoter activity in 293 cells. The biological activity in the conditioned medium (10 ml) was equivalent to that of recombinant LIF (1 ng) (Figure 7b ). If LIF alone is responsible for the activity, the concentration of the cytokine would be about 100 ng/ml. LIF was initially identified as a factor that inhibits the proliferation and induces macrophage differentiation of the mouse myeloid leukemia cell line M1 (Tomida et al., 1984) . By the bioassay using M1 cells, we estimated the concentration of LIF in the conditioned medium of SEKI cells to be more than 100 ng/ml (unpublished results). Treatment of the conditioned medium with anti-IL-6 antibodies did not affect the biological activity. Previous studies (Kamohara et al., 1994; Iseki et al., 1995) using the Quantikine ELISA (R&D Systems) showed that 1-2 ng/ml of LIF was present and other IL-6-type cytokines, such as IL-6, IL-11 and oncostatin M were absent in the conditioned medium of SEKI cells. We recently determined concentrations of LIF by the Quantikine ELISA and detected 1.2-1.8 ng/ml of LIF in the conditioned medium. To our surprise, 100 ng of human LIF produced by CHO cells (Lowe et al., 1989 ) was evaluated as 46 pg by the ELISA. This preparation of LIF is heavily glycosylated with 30% by weight neutral sugar and 12% sialic acid (Schmelzer et al., 1993) . We observed a difference in the degrees of glycosylation of mouse LIF (Tomida et al., 1984) . Nearly all LIF (95%) from L929 cells and 53% of LIF from Ehrlich ascites tumor cells bound to Con A-Sepharose. This immunoassay is calibrated against a purified E. coli-expressed recombinant human LIF and seems to be inadequate to determine exact levels of natural LIF. Although the exact level of LIF secreted by SEKI cells is unknown at the present, the cells secrete LIF enough to activate the HGF promoter. Treatment of SEKI cells with anti-LIF antibodies reduced the HGF promoter activity and phosphorylation of Stat3. These results suggest that the activation of Stat3 and the expression of HGF gene in SEKI cells are mainly dependent on LIF produced endogenously. The treatment of SEKI cells with anti-LIF antibodies reduced 40% of the promoter activity, whereas a mutation in the Stat-binding element reduced 80% of the promoter activity. This discrepancy may be due to the insufficient ability of the anti-LIF antibodies. However, it is also possible that a factor other than LIF participates in the Stat3 activation in SEKI cells, since Stat3 is activated by various cytokines (Akira et al., 1994) , growth factors (Horvath et al., 1995) and oncogenes, such as v-Src (Yu et al., 1995; Bromberg, 2002) . The constitutive activation of Stat3 in primary cancers and tumor-derived cell lines has been frequently reported (Bowman et al., 2000; Bromberg, 2002) . On the other hand, HGF is involved in tumor invasion and metastasis by stimulating the motility of cancer cells and by stimulating angiogenesis (Matsumoto and Nakamura, 1996) . It is likely that the malignancy of cancer cells that contain activated Stat3 is at least partly due to the stimulation of HGF expression in the cancer cells or mesenchymal cells.
Both HGF and LIF are multifunctional cytokines involved in normal development and tissue regeneration (Matsumoto and Nakamura, 1996; Auernhammer and Melmed, 2000) . The biological functions of these cytokines partly overlap. For example, both cytokines are necessary for development of the placenta (Schmidt et al., 1995; Uehara et al., 1995; Ware et al., 1995) , kidneys (Santos et al., 1994; Woolf et al., 1995; Barasch et al., 1999) and neurons (Li et al., 1995; Maina and Klein, 1999) . It is possible that some actions of LIF are dependent on HGF induced by LIF, and that these cytokines cooperate to regulate many biological functions.
Materials and methods
Cells and cell culture
Melanoma cell line, SEKI, was established at the National Cancer Center, Tokyo, Japan (Iseki et al., 1995) . The cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). Human embryo kidney 293 cells were cultured in a 1 : 1 mixture of Ham's F12 and Dulbecco's minimum essential medium supplemented with 10% FBS.
Cytokines and antibodies
Recombinant human LIF was produced in Chinese hamster ovary (CHO) cells and purified to homogeneity as described previously (Lowe et al., 1989; Schmelzer et al., 1993) . Recombinant human HGF was purchased from Pepro Tech. Anti-Stat1 (E-23), anti-Stat3 (C-20), anti-Stat-5 (C-17) and anti-phospho-Stat3 (Y705) antibodies were obtained from Santa Cruz Biotechnology. Monoclonal antiStat3 antibodies were obtained from Transduction Laboratories. Anti-Stat3 (AA 688-722) and anti-phosphotyrosine (4G10) antibodies were obtained from Upstate Biotechnology. Goat anti-LIF (L-9277) and rabbit anti-LIF (Ab-3) antibodies were obtained from Sigma and Calbiochem, respectively.
Real time RT-PCR
The 293 cells were stimulated with 10 ng/ml of recombinant human LIF. Total RNA was extracted from the cells using guanidium thiocyanate. The RNA (0.5 mg) was reversetranscribed using random nonamer primers. PCRs were performed with a LightCycler-FastStart DNA Master SYBR Green I kit (Roche) and Control Kit DNA (Roche). The primer sequences for the HGF gene were as follows: forward, 5 0 -TCACGAGCATGACATGACTCC-3 0 , and reverse, 5 0 -AGCTTACTTGCATCTGGTTCC-3 0 . The cycling conditions were as follows: initial denaturation at 951C for 10 min, followed by 45 cycles of 951C for 15 s, 651C for 10 s and 721C for 12 s.
Plasmid construction
The region of DNA at the 5 0 end of the HGF gene (1029 bp) was obtained by the PCR method with human placental DNA and then subcloned into the XhoI-HindIII sites of luciferase reporter plasmid pGL2-basic (Promega). Deletion constructs HGF-293 and HGF-73 were generated with restriction enzymes, SacI/HindIII and BglII/HindIII, respectively. HGF-181 was generated by PCR using a forward primer, 5 0 -TAGAGCTCTGTTTGGTGCTGTTGAAGG-3 0 , and a reverse primer, 5 0 -ATAAGCTTGCCTGGGTGAAAGAA-TCCTG-3 0 , and then subcloned into the SacI-HindIII sites of the pGL2 vector. Mutations were introduced in the context of the HGF-293 construct by means of the overlap extension technique using PCR. The primers used for these mutations were as follows: for HGF-NFIL6mut, 5 0 -GGGGCGAGaGAGaAgtGGAGGGGGCTG-3 0 and 5 0 -CAGCCCCCTCCacTtCTCtCTCTCGCCCC-3 0 ; for HGF-STATmut, 5 0 -TGTTAAACAGTTTCgcgtCGTAAGAGGGAG-3 0 and 5 0 -CTCCCTCTTACGacgcGAAACTGTTTAACA-3 0 ; for the 5 0 -primer, 5 0 -TGGAGCTCCAGCTTCCAAATTG-3 0 ; and for the 3 0 -primer, 5 0 -ATAAGCTTGCCTGGGTGAAAGAATCCTG-3 0 . Lowercase letters represent nucleotide changes. The dominant-negative Stat3 expression vector (pRc-DStat3B) was derived from pME18S DStat3B (O'Farrell et al., 1998; Tomida et al., 1999) . Stat3 cDNA was prepared by the PCR method using human liver cDNAs (Clontech) as templates. The cDNA was subcloned into the expression vector, pRc/ CMV (Invitrogen).
Transfection of DNA and luciferase assays SEKI and 293 cells (10 5 ) were inoculated into six-well plates 1 day before transfection. The cells were transfected with the HGF promoter constructs or pGL2-basic vector (2 mg/well), and the pRL-TK vector (0.1 mg), using 6 ml of FuGENE 6 reagent (Roche). After 24 h, half of the 293 cultures was treated overnight with 10 ng/ml of LIF. Cell lysates were prepared at 38 h post-transfection. Luciferase activity was determined with a luminometer and a Dual-Luciferase Reporter Assay System (Promega). The activity was normalized as to transfection efficiency using the Renilla luciferase activity of pRL-TK.
Western blot analysis
Phosphorylation of Stat was examined as described previously (Tomida et al., 1999) . Cells were incubated with 10 ng/ml of LIF for 10 min or with anti-LIF antibodies for 20 h. The cells (3 Â 10 6 ) were then harvested and lysed in 400 ml of lysis buffer (1% Triton X-100, 150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 1 mM Na 3 VO 4 , 1mM phenylmethylsulfonyl fluoride (PMSF), 10 mg/ml leupeptin, 10 mg/ml pepstatin and 1 mg/ml aprotinin) for 5 min on ice. Supernatants were obtained by centrifugation and incubated with antibodies to Stat3 or Stat1. The immune complexes were precipitated with Protein A-Sepharose and then separated by SDS-polyacrylamide gel electrophoresis, followed by immunoblotting with anti-phospho-Stat3 (Y705) or anti-phosphotyrosine antibodies. The blots were stripped and reprobed with antibodies to Stat3 or Stat1. The immune complex was visualized as chemiluminescence.
Electrophoretic mobility shift assays
The 293 cells were transfected with pRc-Stat3. After 2 days, the cells were stimulated with 10 ng/ml of LIF for 10 min. Nuclear extracts were prepared from 10 7 cells by the method described previously (Akira et al., 1994) with minor modifications. The cells were washed two times with cold phosphate-buffered saline (PBS) and then suspended in 500 ml of buffer A (0.1% Nonidet P-40, 10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 1 mM Na 3 VO 4 , 0.5 mM PMSF, and 2 mg each of leupeptin, pepstatin and aprotinin per ml) for 10 min on ice. Nuclei were pelleted and suspended in 100 ml of buffer C (50 mM HEPES, pH 7.9, 420 mM NaCl, 0.1 mM EDTA, 2% glycerol, 1 mM dithiothreitol, 1 mM Na 3 VO 4 , 0.5 mM PMSF, and 2 mg each of leupeptin, pepstatin and aprotinin per ml). After gentle agitation for 30 min at 41C, the extracted nuclei were centrifuged for 5 min at 20 000 g. The supernatant was collected and stored at À1501C. The nuclear extract (5 mg) was incubated with 20 pmol of unlabeled oligonucleotide or 2 mg of antibodies and 4 mg of poly(dI-dC) (Amersham Biosciences) in binding buffer (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM EDTA, 1 mM MgCl 2 , 0.5 mM dithiothreitol, 4% glycerol, 0.5 mM PMSF, 1 mM Na 3 VO 4 , and 2 mg each of leupeptin, pepstatin and aprotinin per ml) at room temperature for 20 min, and then incubated with 0.1 pmol of 32 P-labeled oligonucleotide probe at room temperature for a further 20 min. The DNA-protein complexes were separated by electrophoresis on a 6% polyacrylamide gel in 0.5 Â TBE buffer (45 mM Tris-borate and 1 mM EDTA). The gel was dried and autoradiographed. The oligonucleotides used for the EMSA were: HGF (À105BÀ86), 5 0 -AGTTTCTTACCG-TAAGAGGG-3 0 ; HGF (Mutant), 5 0 -AGTTTCgcgtCGTAA-GAGGG-3 0 ; HGF (À120BÀ101), 5 0 -GGGCTGTTGTTA-AACAGTTT-3 0 ; and Stat3 consensus (acute-phase response element) (Yu et al., 1995) , 5 0 -GATCCTTCTGGGAATTCC-TAG-3 0 . The double-stranded oligonucleotides were formed by annealing complementary oligonucleotides. The oligonucleotide probe, HGF (À105 BÀ86), was labeled with [g-32 P]ATP (3000 Ci/mmol, Amersham Biosciences), using T4 polynucleotide kinase, and purified by a spin column.
